Boston Scientific generated net sales of $5.138 billion in the third quarter of 2026, growth of 1.5 percent on a reported, operational and organic basis against the same quarter a year earlier, the company said on October 28 in results furnished to the SEC. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, down from $755 million, or $0.51 per share, a year earlier. Adjusted earnings per share were $0.73, against $0.75 a year earlier and against the $0.80 to $0.82 the company had guided for the quarter in July, before the cyberattack.
Chief executive Mike Mahoney called it a challenging year and credited the company’s teams for responding to the cybersecurity incident with urgency to restore operations. The incident, first identified on August 25, disrupted manufacturing, order processing and customer shipments, and in September the company warned it was unlikely to meet its third quarter and full year guidance.
The segment detail shows where the damage landed. MedSurg sales rose 0.6 percent reported to $1.733 billion, with endoscopy down 0.8 percent and urology down 3.2 percent, partly offset by neuromodulation growth of 13.1 percent. Cardiovascular sales rose 1.9 percent to $3.406 billion. By region, United States sales rose 0.5 percent, Europe, Middle East and Africa rose 4.4 percent reported, Asia-Pacific fell 0.6 percent, and Latin America and Canada rose 16.0 percent.
Guidance now reflects a slow finish to the year. Boston Scientific estimates full year 2026 net sales growth of approximately 4.25 percent reported and 3.75 percent organic, with adjusted earnings per share of $3.16 to $3.18, and it expects fourth quarter sales to decline by approximately 3.0 to 1.0 percent against the prior year. The company also reported device progress in the quarter, including first enrollment in the Elite AF trial of its next generation WATCHMAN device, Food and Drug Administration 510(k) clearances in its StoneSmart urology line, and a strategic collaboration with Heartflow on AI powered coronary procedure planning.